Onesource reverses stance on DDC contracts, accelerates capacity
In Q1 FY27 concall, management reveals it is now accepting new manufacturing service agreements after prioritizing commercial sales, and pulls forward soft-gelatin fill timeline to 12-15 months.
— 3 earlier stories on Onesource Specialty Pharma Ltd. →What's new
- Onesource reversed its prior stance, now accepting new manufacturing service agreements for drug-device combos.
- Soft-gelatin capacity fill timeline accelerated to 12-15 months from ~2 years.
- Current DDC capacity fully utilized; second line commercializing this quarter.
Why this matters
The strategic pivot suggests demand for DDC services is stronger than anticipated, justifying capacity acceleration. The reiteration of FY28 targets ($400M revenue, 40% EBITDA) provides a clear benchmark, but the concall summary itself carries limited incremental price impact since the live discussion was the original news event.
What we're watching
- Whether the new service agreements materialize into near-term revenue.
- Soft-gelatin capacity ramp-up and utilization rates over the next 12-15 months.
- EBITDA margin trajectory given the revenue mix shift between services and commercial sales.
The full read
Onesource Specialty Pharma reported a strong first quarter: ₹4,490 million in revenue, up 37% year-on-year, with EBITDA of ₹1,233 million. But the numbers took a back seat to strategy. On the July 25 concall, management revealed it had reversed its stance on drug-device combination products: the company is now accepting new manufacturing service agreements, after previously saying it would focus solely on commercial sales. It also accelerated the fill timeline for its expanded soft-gelatin capacity to 12-15 months from roughly two years. Current DDC capacity is fully utilised; a second line commercialises this quarter. Management held firm on its FY28 targets of $400 million organic revenue and 40% EBITDA margins. The concall summary captures these pivots cleanly, though as a post-event document, its market impact is limited since the live discussion was the original news.
Questions answered
- What did Onesource reveal about its DDC strategy?
- Onesource said it has started accepting new manufacturing service agreements for drug-device combination products, reversing its earlier stance of prioritizing commercial sales over services.
- How is the soft-gelatin capacity expansion timeline changing?
- The expected fill timeline was pulled forward to 12-15 months from roughly two years, indicating faster-than-expected demand.
- What are the FY28 targets management reiterated?
- Management reiterated targets of $400 million in organic revenue and 40% EBITDA margins for fiscal 2028.
- Is DDC capacity fully utilized now?
- Yes, management noted current DDC capacity is fully utilized, and a second line will commercialize in the current quarter.
- What was Onesource's Q1 FY27 revenue and EBITDA?
- Revenue was ₹4,490 million, up 37% YoY, and EBITDA was ₹1,233 million.
Onesource Specialty Pharma Ltd.
Latest quarter · Mar 2026
Strength & growth
Story so far
All notes on ONESOURCE →- 25 Jul 2026 · 11:09 AM IST Onesource reverses stance on DDC contracts, accelerates capacity
- 11d ago OneSource partners with Formycon for biosimilars, terms undisclosed
- 16d ago Onesource says Dr. Reddy's Semaglutide delay won't hit its ops
- 23d ago OneSource gets single FDA observation, PAT collapse looms larger